The Short and Long Term Effects of Exercise Training in Non-cystic Fibrosis Bronchiectasis--a Randomised Controlled Trial

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2014 Apr 16

PMID 24731015

Citations 47

Authors

Annemarie L Lee

Catherine J Hill

Nola Cecins

Sue Jenkins

Christine F McDonald

Angela T Burge

Linda Rautela

Robert G Stirling

Philip J Thompson

Anne E Holland

Affiliations

Soon will be listed here.

Abstract

Background: Exercise training is recommended for non-cystic fibrosis (CF) bronchiectasis, but the long-term effects are unclear. This randomised controlled trial aimed to determine the effects of exercise training and review of airway clearance therapy (ACT) on exercise capacity, health related quality of life (HRQOL) and the incidence of acute exacerbations in people with non-CF bronchiectasis.

Methods: Participants were randomly allocated to 8 weeks of supervised exercise training and review of ACT, or control. Primary outcomes of exercise capacity and HRQOL (Chronic respiratory disease questionnaire) and secondary outcomes of cough-related QOL (Leicester cough questionnaire) and psychological symptoms (Hospital anxiety and depression scale) were measured at baseline, following completion of the intervention period and at 6 and 12 months follow up. Secondary outcomes of the exacerbation rate and time to first exacerbation were analysed over 12 months.

Results: Eighty-five participants (mean FEV1 74% predicted; median Modified Medical Research Council Dyspnoea grade of 1 (IQR [1-3]) were included. Exercise training increased the incremental shuttle walk distance (mean difference to control 62 m, 95% CI 24 to 101 m) and the 6-minute walking distance (mean difference to control 41 m, 95% CI 19 to 63 m), but these improvements were not sustained at 6 or 12 months. Exercise training reduced dyspnoea (p = 0.009) and fatigue (p = 0.01) but did not impact on cough-related QOL or mood. Exercise training reduced the frequency of acute exacerbations (median 1[IQR 1-3]) compared to the control group (2[1-3]) over 12 months follow up (p = 0.012), with a longer time to first exacerbation with exercise training of 8 months (95% CI 7 to 9 months) compared to the control group (6 months [95% CI 5 to 7 months], p = 0.047).

Conclusions: Exercise training in bronchiectasis is associated with short term improvement in exercise capacity, dyspnoea and fatigue and fewer exacerbations over 12 months.

Trial Registry: ClinicalTrials.gov (NCT00885521).

Citing Articles

Clinical characteristics and economic impact of acute hospitalisations due to bronchiectasis exacerbations among adult Indigenous Australians in the Top End Northern Territory.

Berhane T, Bayfield A, Howarth T, James K, Muthumala A, Mo L Intern Med J. 2025; 55(3):526-529.

PMID: 39981580 PMC: 11900846. DOI: 10.1111/imj.16654.

Patient-managed interventions for adults with bronchiectasis: evidence, challenges and prospects.

Spinou A, Lee A, ONeil B, Oliveira A, Shteinberg M, Herrero-Cortina B Eur Respir Rev. 2024; 33(174).

PMID: 39477356 PMC: 11522970. DOI: 10.1183/16000617.0087-2024.

The effect of graded exercise therapy on fatigue in people with serious respiratory illness: a systematic review.

Burge A, Gadowski A, Romero L, Vagheggini G, Spathis A, Smallwood N Eur Respir Rev. 2024; 33(174).

PMID: 39384307 PMC: 11462302. DOI: 10.1183/16000617.0027-2024.

Exacerbations of bronchiectasis.

De Angelis A, Johnson E, Sutharsan S, Aliberti S Eur Respir Rev. 2024; 33(173).

PMID: 39048130 PMC: 11267293. DOI: 10.1183/16000617.0085-2024.

Bronchiectasis management in adults: state of the art and future directions.

Choi H, McShane P, Aliberti S, Chalmers J Eur Respir J. 2024; 63(6).

PMID: 38782469 PMC: 11211698. DOI: 10.1183/13993003.00518-2024.

References

Hawthorne G, Osborne R . Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust N Z J Public Health. 2005; 29(2):136-42. DOI: 10.1111/j.1467-842x.2005.tb00063.x. View

Angrill J, Agusti C, De Celis R, Rano A, Gonzalez J, Sole T . Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002; 57(1):15-9. PMC: 1746176. DOI: 10.1136/thorax.57.1.15. View

Joish V, Spilsbury-Cantalupo M, Operschall E, Luong B, Boklage S . Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy. 2013; 11(3):299-304. DOI: 10.1007/s40258-013-0027-z. View

Schulz K, Altman D, Moher D . CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010; 8:18. PMC: 2860339. DOI: 10.1186/1741-7015-8-18. View

Williams J, Singh S, Sewell L, Guyatt G, Morgan M . Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax. 2001; 56(12):954-9. PMC: 1745990. DOI: 10.1136/thorax.56.12.954. View

Zigmond A, SNAITH R . The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6):361-70. DOI: 10.1111/j.1600-0447.1983.tb09716.x. View

Murray M, Turnbull K, MacQuarrie S, Pentland J, Hill A . Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009; 34(1):125-31. DOI: 10.1183/09031936.00160508. View

Lee A, Cecins N, Hill C, Holland A, Rautela L, Stirling R . The effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis: protocol for a randomised controlled trial. BMC Pulm Med. 2010; 10:5. PMC: 2845119. DOI: 10.1186/1471-2466-10-5. View

Newall C, Stockley R, Hill S . Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax. 2005; 60(11):943-8. PMC: 1747238. DOI: 10.1136/thx.2004.028928. View

10.

King P, Holdsworth S, Freezer N, Villanueva E, Holmes P . Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med. 2006; 100(12):2183-9. DOI: 10.1016/j.rmed.2006.03.012. View

11.

Loebinger M, Wells A, Hansell D, Chinyanganya N, Devaraj A, Meister M . Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009; 34(4):843-9. DOI: 10.1183/09031936.00003709. View

12.

Finklea J, Khan G, Thomas S, Song J, Myers D, Arroliga A . Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. Respir Med. 2010; 104(6):816-21. DOI: 10.1016/j.rmed.2009.11.021. View

13.

Mahler D, Wells C . Evaluation of clinical methods for rating dyspnea. Chest. 1988; 93(3):580-6. DOI: 10.1378/chest.93.3.580. View

14.

Barker A . Bronchiectasis. N Engl J Med. 2002; 346(18):1383-93. DOI: 10.1056/NEJMra012519. View

15.

Chang A, Bilton D . Exacerbations in cystic fibrosis: 4--Non-cystic fibrosis bronchiectasis. Thorax. 2008; 63(3):269-76. DOI: 10.1136/thx.2006.060913. View

16.

Singh S, Morgan M, Scott S, Walters D, Hardman A . Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax. 1992; 47(12):1019-24. PMC: 1021093. DOI: 10.1136/thx.47.12.1019. View

17.

Lachin J . Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000; 21(3):167-89. DOI: 10.1016/s0197-2456(00)00046-5. View

18.

King P, Holdsworth S, Freezer N, Villanueva E, Gallagher M, Holmes P . Outcome in adult bronchiectasis. COPD. 2006; 2(1):27-34. DOI: 10.1081/copd-200050685. View

19.

. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111-7. DOI: 10.1164/ajrccm.166.1.at1102. View

20.

Santamato A, Ranieri M, Panza F, Frisardi V, Marvulli R, Filoni S . Pulmonary rehabilitation for patients with bronchiectasis: case reports. Eur J Phys Rehabil Med. 2012; 48(2):293-8. View